# Using a Brief Body Sway Assessment Device to Track Balance Differences across the Huntington's Disease Integrated Staging System Spectrum

**Authors:** Japleen Kaur, Nadeen Youhanan, Krisha Bagga, Andrew Hall, Paul E. Gilbert, Daniel J. Goble, Jody Corey‐Bloom

PMC · DOI: 10.1002/mdc3.70288 · Movement Disorders Clinical Practice · 2025-09-08

## TL;DR

This study shows that balance impairment in Huntington's disease can be detected early and worsens as the disease progresses, using a portable sway assessment device.

## Contribution

The study introduces a novel use of a portable balance device to track balance changes across Huntington's disease stages, including pre-symptomatic individuals.

## Key findings

- Balance impairment is detectable in early Huntington's disease stages before overt motor symptoms.
- Total body sway increases progressively from stage 0/1 to stage 3 of Huntington's disease.
- The BTrackS Balance Plate can distinguish between healthy controls and early-stage Huntington's disease participants with 74.5% sensitivity.

## Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin gene on chromosome 4, leading to progressive cognitive decline, motor impairment, and functional disability. Although balance impairment is recognized in HD, its onset and evolution with disease stage remain poorly understood.

The aim was to track the onset and evolution of balance impairment in HD with progression of disease stage using the BTrackS Balance Plate.

Total body sway (TBS) was assessed in 123 gene‐positive participants and 33 healthy controls (HC) using the BTrackS Balance Plate and laptop software. The prognostic index–derived Huntington's Disease Integrated Staging System (HD‐ISS) was used to stratify these subjects into stage 0/1 (n = 51), stage 2 (n = 38), and Stage 3 (n = 34). Nonparametric receiver operating characteristic curve analysis was used to compute optimal cutoff values for TBS.

Balance assessment revealed significant differences in TBS between HCs and gene‐positive participants (P < 0.001). TBS varied significantly across disease stages (P < 0.001), with mean values of 9.56 cm (stage 0/1), 14.46 cm (stage 2), and 28.26 cm (Stage 3). The comparison between HCs and stage 0/1 individuals revealed strong discrimination (area under the curve [AUC] = 0.709), with a threshold of 7.72 cm achieving 74.5% sensitivity. The most robust discrimination emerged between stage 2 and Stage 3 participants (AUC = 0.71), with a threshold of 11.85 cm at 82.4% sensitivity.

In conclusion, this cross‐sectional study demonstrates that balance impairment is an early and progressive feature of HD, detectable even before the onset of overt motor symptoms.

## Linked entities

- **Genes:** LOC101450258 (uncharacterized LOC101450258) [NCBI Gene 101450258]
- **Diseases:** Huntington's disease (MONDO:0007739)

## Full-text entities

- **Genes:** HTT (huntingtin) [NCBI Gene 3064] {aka HD, IT15, LOMARS}
- **Diseases:** HD (MESH:D006816), autosomal dominant neurodegenerative disorder (MESH:D019636), cognitive decline (MESH:D003072), balance impairment (MESH:D060825), functional disability (MESH:D003291), motor impairment (MESH:D000068079)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911521/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12911521/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911521/full.md

---
Source: https://tomesphere.com/paper/PMC12911521